by B2i | Feb 13, 2024 | Press Releases
JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 — Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic...
by B2i | Feb 6, 2024 | Press Releases
JUPITER, Fla., Feb. 06, 2024 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation...
by B2i | Feb 1, 2024 | Press Releases
JUPITER, Fla., Feb. 01, 2024 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
by B2i | Jan 2, 2024 | Press Releases
JUPITER, Fla., Jan. 02, 2024 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
by B2i | Nov 30, 2023 | Press Releases
JUPITER, Fla., Nov. 30, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
by B2i | Nov 29, 2023 | Press Releases
Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse Events reportedFinal Clinical Study Report available in the coming weeks JUPITER, Fla., Nov. 29, 2023...
